Watson Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Watson Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $63.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Watson Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $63.4M Trade | TransData Nexus

Watson Pharma Private Limited

Indian Pharmaceutical Exporter · CNS & Psychiatric Specialist · $63.4M Total Trade · DGFT Verified

Watson Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $63.4M across 14 products in 7 therapeutic categories. Based on 1,560 verified export shipments from Indian Customs (DGFT) records, Watson Pharma Private Limited is the #1 Indian exporter in 1 product including Alprazolam. Top exports include Gabapentin ($39.1M), Alprazolam ($8.4M), Hydrochlorothiazide ($4.1M).

Watson Pharma Private Limited — Export Portfolio & Destination Treemap

Watson Pharma Private Limited pharmaceutical export portfolio — 14 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Watson Pharma Private Limited? — Company Overview & Market Position

Watson Pharma Private Limited, established on October 21, 2005, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC156968. As of March 31, 2025, Watson Pharma reported an authorized capital of ₹200.00 crore and a paid-up capital of ₹161.98 crore. The company employs approximately 1,125 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector.

Watson Pharma specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company's product portfolio is notably concentrated, with the top five products accounting for 89.4% of its total export value. This concentration underscores Watson Pharma's strategic focus on specific high-demand medications.

What Does Watson Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Gabapentin$39.1M 2

Product Portfolio — Top 14 by Export Value

Watson Pharma Private Limited exports 14 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gabapentin	CNS & Psychiatric	$39.1M	882	4.6%	5
2	Alprazolam	CNS & Psychiatric	$8.4M	261	46.5%	1
3	Hydrochlorothiazide	Diuretics	$4.1M	102	1.0%	10
4	Prednisone	Respiratory	$3.2M	64	10.8%	3
5	Dapagliflozin	Advanced Diabetes Medications	$1.8M	63	3.7%	7
6	Simvastatin	Cardiovascular	$1.1M	33	0.9%	15
7	Febuxostat	Lipid & Metabolism	$1.1M	21	2.1%	7
8	Allopurinol	Lipid & Metabolism	$971.9K	24	0.2%	12
9	Verapamil	Cardiovascular	$850.0K	17	0.8%	7
10	Propranolol	Cardiovascular	$837.6K	45	1.4%	7
11	Theophylline	Respiratory	$518.1K	13	3.3%	6
12	Lisinopril	Cardiovascular	$505.3K	17	0.8%	11
13	Colchicine	Lipid & Metabolism	$450.0K	9	2.1%	6
14	Minocycline	Advanced Antibiotics	$450.0K	9	2.0%	3

Watson Pharma Private Limited exports 14 pharmaceutical products across 7 therapeutic categories with a total export value of $63.4M. The company is the #1 Indian exporter in 1 product: Alprazolam. The top category is CNS & Psychiatric (75.0% of portfolio), followed by Diuretics (6.4%), indicating a concentrated portfolio with the top 5 products accounting for 89.4% of total export value.

Watson Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Watson Pharma operates manufacturing facilities in Mumbai, Maharashtra, and Verna, Goa. The Mumbai facility is situated at 8th Floor, Tower C, Times Square, Andheri Kurla Road, Gamdevi, Marol, Andheri East, Mumbai, Maharashtra, 400059. The Goa facility is located in Verna, Goa - 403722. These facilities are equipped to produce a diverse range of pharmaceutical formulations, ensuring compliance with international quality standards. The strategic locations facilitate efficient distribution and access to key markets.

3Key Leadership

As of March 2026, Watson Pharma's leadership comprises several key executives:

Nishank Bhargava: Director, appointed on February 24, 2022.
Agnieszka Monika Lubkowska: Director, appointed on June 26, 2024.
Chandrasekhar Bhagwan Sinha: Additional Director, appointed on August 8, 2025.
Vivek Jugal Kishor Saraf: Company Secretary, appointed on November 24, 2016.
Hemant Kumar Manilal Mamania: Director, appointed on January 3, 2022.

These appointments reflect the company's commitment to strong governance and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Watson Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Watson Pharma has established a significant presence in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has secured approvals for its finished pharmaceutical formulations, ensuring compliance with the stringent regulatory standards of these regions. This regulatory compliance facilitates market access and underscores Watson Pharma's commitment to quality and safety. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory requirements has been instrumental in building trust and expanding its footprint in these markets.

2Emerging Markets

Watson Pharma has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), enabling access to these regions. This prequalification is a testament to the quality and safety of Watson Pharma's products, facilitating smoother entry and acceptance in these markets. The company's focus on emerging markets aligns with its growth strategy, leveraging the increasing demand for affordable and quality pharmaceuticals in these regions.

3Geographic Strategy

Watson Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Watson Pharma has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has received approvals for its Abbreviated New Drug Applications (ANDAs), allowing it to market generic pharmaceutical products in the U.S. Additionally, Watson Pharma has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, with no significant observations reported, indicating a strong compliance record.

2WHO & EU GMP

Watson Pharma's manufacturing facilities are prequalified by the World Health Organization (WHO), affirming the quality and safety of its products. The company holds European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating adherence to EU standards. These certifications are crucial for market access in Europe and other regions that recognize EU GMP standards. The company's commitment to maintaining these certifications underscores its dedication to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Watson Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical industry, Watson Pharma faces competition from several key players in overlapping therapeutic categories. Competitors include established pharmaceutical companies with a diverse product portfolio and a global presence. Market share comparisons indicate that Watson Pharma holds a leading position in certain therapeutic areas, particularly in the production of Alprazolam, where it is the market leader. The company's focus on high-demand medications and its strategic market positioning contribute to its competitive edge.

2Key Differentiators

Watson Pharma's key differentiators include its concentrated product portfolio, with the top five products accounting for 89.4% of its total export value, and its strong presence in both regulated and emerging markets. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications. Additionally, Watson Pharma's strategic focus on high-demand medications, such as Alprazolam, positions it as a market leader in specific therapeutic areas.

3Strategic Position

Watson Pharma's current strategic direction emphasizes the production of generic pharmaceutical formulations, with a focus on high-demand medications. The company's future outlook includes expanding its presence in emerging markets and exploring opportunities in specialty pharmaceuticals and contract development and manufacturing organizations (CDMO). This strategic positioning aims to leverage global pharmaceutical demand and enhance the company's growth trajectory.

Buyer Due Diligence Brief — Evaluating Watson Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Watson Pharma has a strong track record in pharmaceutical manufacturing, with a total export value of $63.4 million USD and 1,560 shipments across 14 products in 7 therapeutic categories. The company's portfolio concentration, with the top five products accounting for 89.4% of total export value, indicates a focused approach to high-demand medications. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering products from Watson Pharma:

FDA Facility Registration: Confirm the registration status of Watson Pharma's manufacturing facilities with the U.S. Food and Drug Administration.
WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization.
EU GMP Certificate: Verify the validity of the European Union Good Manufacturing Practice certificate.

Frequently Asked Questions — Watson Pharma Private Limited

How many pharmaceutical products does Watson Pharma Private Limited export from India?

Watson Pharma Private Limited exports 14 pharmaceutical products across 7 therapeutic categories. The top exports are Gabapentin ($39.1M), Alprazolam ($8.4M), Hydrochlorothiazide ($4.1M), Prednisone ($3.2M), Dapagliflozin ($1.8M). Total export value is $63.4M.

What is Watson Pharma Private Limited's total pharmaceutical export value?

Watson Pharma Private Limited's total pharmaceutical export value is $63.4M, based on 1,560 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Watson Pharma Private Limited the #1 Indian exporter?

Watson Pharma Private Limited is the #1 Indian exporter in 1 products: Alprazolam (46.5% market share).

What therapeutic categories does Watson Pharma Private Limited cover?

Watson Pharma Private Limited exports across 7 therapeutic categories. The largest are CNS & Psychiatric (75.0%, 2 products), Diuretics (6.4%, 1 products), Respiratory (5.9%, 2 products).

Get Full Watson Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.